Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus

Página do item simplificado
dc.contributor.authorSader, Hello S. [UNIFESP]
dc.contributor.authorJones, Ronald N.
dc.contributor.institutionJMI Labs Inc
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionTufts Univ
dc.date.accessioned2016-01-24T14:27:19Z
dc.date.available2016-01-24T14:27:19Z
dc.date.issued2012-06-01
dc.description.abstractCoagulase-negative Staphylococcus spp. (CoNS) represent a major cause of bloodstream infections, especially in patients with prosthetic devices and intravenous catheters. We evaluated the activity of daptomycin in comparison to vancomycin and teicoplanin against a large collection of 22,024 CoNS isolates causing clinically significant infections from 283 medical centers over 9 years (2002-2010) and tested for susceptibility by broth microdilution methods against daptomycin and numerous comparators. Overall, daptomycin (MIC50/90, 0.25/0.5 mu g/mL) inhibited 99.8% of CoNS at the susceptible breakpoint of <= 1 mu g/mL and was 4- to 16-fold more active than vancomycin (MIC50/90, 1/2 mu g/mL; >99.9% susceptible). All species showed >= 99.6% susceptibility to daptomycin, except Staphylococcus auricularis (95.1%), S. capitis (99.0%), S. warneri (98.8%), and S. sciuri. S. sciuri represented only 0.2% of the collection (46 strains) and exhibited decreased susceptibility to daptomycin (MIC50/90, 1/2 mu g/mL; 71.7% susceptible). in contrast, S. sciuri exhibited high susceptibility to vancomycin and teicoplanin (highest MIC at 2 mu g/mL for both drugs). in summary, daptomycin exhibited species-specific activity among CoNS, especially versus S. sciuri. No correlation between decreased susceptibility to daptomycin and the glycopeptides tested was observed. (C) 2012 Elsevier Inc. All rights reserved.en
dc.description.affiliationJMI Labs Inc, N Liberty, IA 52317 USA
dc.description.affiliationUniversidade Federal de São Paulo, BR-04023 São Paulo, Brazil
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, BR-04023 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipAchaogen
dc.description.sponsorshipAmerican Proficiency Institute (API)
dc.description.sponsorshipAnacor
dc.description.sponsorshipAstellas
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipBayer
dc.description.sponsorshipbioMerieux
dc.description.sponsorshipCempra
dc.description.sponsorshipCerexa
dc.description.sponsorshipContrafect
dc.description.sponsorshipCubist
dc.description.sponsorshipDaiichi
dc.description.sponsorshipDipexium
dc.description.sponsorshipEnanta
dc.description.sponsorshipFuriex
dc.description.sponsorshipGlaxoSmithKline
dc.description.sponsorshipJohnson & Johnson (Ortho McNeil)
dc.description.sponsorshipLegoChem Biosciences Inc.
dc.description.sponsorshipMeiji Seika Kaisha
dc.description.sponsorshipMerck
dc.description.sponsorshipNabriva
dc.description.sponsorshipNovartis
dc.description.sponsorshipParatek
dc.description.sponsorshipPfizer (Wyeth)
dc.description.sponsorshipPPD Therapeutics
dc.description.sponsorshipPremier Research Group
dc.description.sponsorshipRempex
dc.description.sponsorshipRib-X Pharmaceuticals
dc.description.sponsorshipSeachaid
dc.description.sponsorshipShionogi
dc.description.sponsorshipThe Medicines Co.
dc.description.sponsorshipTheravance
dc.description.sponsorshipThermoFisher
dc.description.sponsorshipTREK Diagnostics
dc.format.extent212-214
dc.identifierhttp://dx.doi.org/10.1016/j.diagmicrobio.2012.02.005
dc.identifier.citationDiagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 73, n. 2, p. 212-214, 2012.
dc.identifier.doi10.1016/j.diagmicrobio.2012.02.005
dc.identifier.issn0732-8893
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/34954
dc.identifier.wosWOS:000305102100022
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofDiagnostic Microbiology and Infectious Disease
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectStaphylococcus sciurien
dc.subjectVancomycinen
dc.subjectTeicoplaninen
dc.titleAntimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcusen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral